Literature DB >> 23465155

Endoscopic correction of VUR using vantris as a new non-biodegradable tissue augmenting substance: three years of prospective follow-up.

Boris Chertin1, Wael Abu Arafeh, Alexander Zeldin, Israel A Ostrovsky, Stanislav Kocherov.   

Abstract

OBJECTIVE: To evaluate the efficacy of Vantris in children with vesicoureteral reflux (VUR) after 3 years of prospective follow-up.
MATERIAL AND METHODS: Over the last 3 years, 109 children (72 girls and 37 boys) with a mean age of 6.2 ± 3.4 years (mean ± SD) underwent endoscopic correction of reflux using Vantris. VUR was unilateral in 53 and bilateral in 56 patients comprising 165 renal refluxing units (RRUs). Of these, primary VUR was present in 139 RRUs (84.2%) and 26 (15.8%) were complex cases. Ultrasound scan was performed 1 month, 1 year, and 3 years after injection, and voiding cystourethrogram (VCUG) was performed 3 months, 1 year, and 3 years after endoscopic correction.
RESULTS: The reflux was corrected in 153 RRUs (92.7%) after a single injection and in 7 RRUs (4.2%) after a second injection. In 5 RRUs (3.1%), VUR downgraded to grade I (3 RRUs) and grade II (2 RRUs) and they were taken off antibiotic prophylaxis. Two patients (1.8%) had afebrile urinary tract infections (UTIs) and 2 patients (1.8%) developed febrile UTI. VCUG was performed in 32 of 71 children (39.1%) who completed 1 year and in 6 of 15 (40%) who completed 3 years of follow-up. None showed VUR recurrence. Ultrasound scan demonstrated normal appearance of kidneys in all but 2 patients (1.8%). One patient required stent insertion because of deterioration of hydronephrosis that resulted in complete resolution of obstruction and another patient required ureteral reimplantation.
CONCLUSION: Our data show that Vantris injection provides a high level of reflux resolution with good clinical outcome during prospective follow-up.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23465155     DOI: 10.1016/j.urology.2013.01.024

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  5 in total

1.  Endoscopic correction of complex cases of vesicoureteral reflux utilizing Vantris as a new non-biodegradable tissue-augmenting substance.

Authors:  Boris Chertin; Wael Abu Arafeh; Stanislav Kocherov
Journal:  Pediatr Surg Int       Date:  2014-04       Impact factor: 1.827

2.  Comparison of histopathological characteristics of polyacrylate polyalcohol copolymer with dextranomer/hyaluronic acid after injection beneath the bladder mucosa layer: a rabbit model.

Authors:  Abdol-Mohammad Kajbafzadeh; Shabnam Sabetkish; Reza Khorramirouz; Nastaran Sabetkish
Journal:  Int Urol Nephrol       Date:  2017-02-16       Impact factor: 2.370

3.  Randomized clinical trial between polyacrylate-polyalcohol copolymer (PPC) and dextranomer-hyaluronic acid copolymer (Dx/HA) as bulking agents for endoscopic treatment of primary vesicoureteral reflux (VUR).

Authors:  L García-Aparicio; E Blázquez-Gómez; O Martin; S Pérez-Bertólez; J Arboleda; A Soria; X Tarrado
Journal:  World J Urol       Date:  2018-05-03       Impact factor: 4.226

4.  The outcomes of two different bulking agents (dextranomer hyaluronic acid copolymer and polyacrylate-polyalcohol copolymer) in the treatment of primary vesico-ureteral reflux.

Authors:  Hakan Taşkinlar; Dincer Avlan; Gokhan Berktug Bahadir; Ali Delibaş; Ali Nayci
Journal:  Int Braz J Urol       Date:  2016 May-Jun       Impact factor: 1.541

5.  Endoscopic correction of vesicoureteral reflux in children using polyacrylate-polyalcohol copolymer (Vantris): 5-years of prospective follow-up.

Authors:  Stanisław Warchoł; Grażyna Krzemień; Agnieszka Szmigielska; Przemysław Bombiński; Krzysztof Toth; Teresa Dudek-Warchoł
Journal:  Cent European J Urol       Date:  2017-07-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.